A COPD Quality Improvement Program(QIP)
Launched by SHENZHEN PEOPLE'S HOSPITAL · Nov 27, 2022
Trial Information
Current as of January 13, 2025
Unknown status
Keywords
ClinConnect Summary
The COPD Quality Improvement Program (QIP) is a study aimed at improving the care of patients with Chronic Obstructive Pulmonary Disease (COPD) in China. The program focuses on creating and following quality standards for managing COPD, which includes better ways to diagnose the condition, assess patients, and provide appropriate treatments and follow-up care. By standardizing how COPD is managed, the goal is to help patients receive timely and effective care, which can lead to better health outcomes.
To participate in this trial, you need to be diagnosed with COPD, be at least 40 years old, and have experienced two moderate or one severe flare-up of your symptoms in the past year. You also need to be able to understand and sign a consent form to join. If you're eligible, you can expect to be part of a program that aims to improve your care and management of COPD, making it easier for you to get the right treatments and support you need.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosed with COPD
- • 2. Aged 40 years or older
- • 3. CAT≥10
- • 4. With exacerbation history:
- • 1. at least 2 moderate or 1 severe exacerbation in the previous year
- • 2. or 1 moderate exacerbation in the previous year with FEV1 \<50% predicted value at baseline;
- • 5. Must able to sign the informed consent form
- Exclusion Criteria:
- • 1. Patients on triple therapy at baseline with a LAMA, LABA, and inhaled corticosteroid (ICS) combination (Including open triple and fix-dose triple)
- • 2. Significant diseases or conditions other than COPD, which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study
- • 3. Patients who are currently involved in any other interventional studies
Trial Officials
Rongchang Chen, Professor
Principal Investigator
Shenzhen People's Hospital
About Shenzhen People's Hospital
Shenzhen People's Hospital is a leading medical institution in China, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital is committed to improving patient outcomes by exploring novel therapies and treatment modalities across various medical fields. With a state-of-the-art facility and a team of experienced healthcare professionals, Shenzhen People's Hospital fosters a collaborative environment for clinical research, ensuring adherence to rigorous ethical standards and regulatory requirements. Their focus on patient-centered care and commitment to scientific advancement positions them as a key player in the landscape of medical research in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenzhen, Guang Dong, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials